Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 553

1.

Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan.

Matsumura Y, Yamamoto M, Higuchi T, Komori T, Tsuboi F, Hayashi A, Sugimoto Y, Hotta G, Matsushima A, Nagao M, Takakura S, Ichiyama S.

Int J Antimicrob Agents. 2012 Aug;40(2):158-62. doi: 10.1016/j.ijantimicag.2012.04.013.

PMID:
22743014
2.

Molecular and clinical characterization of plasmid-mediated AmpC β-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum β-lactamase-producing and non-resistant E. coli bacteraemia.

Matsumura Y, Nagao M, Iguchi M, Yagi T, Komori T, Fujita N, Yamamoto M, Matsushima A, Takakura S, Ichiyama S.

Clin Microbiol Infect. 2013 Feb;19(2):161-8. doi: 10.1111/j.1469-0691.2012.03762.x.

3.

Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.

Blanco M, Alonso MP, Nicolas-Chanoine MH, Dahbi G, Mora A, Blanco JE, López C, Cortés P, Llagostera M, Leflon-Guibout V, Puentes B, Mamani R, Herrera A, Coira MA, García-Garrote F, Pita JM, Blanco J.

J Antimicrob Chemother. 2009 Jun;63(6):1135-41. doi: 10.1093/jac/dkp122.

4.

Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.

Yokota S, Sato T, Okubo T, Ohkoshi Y, Okabayashi T, Kuwahara O, Tamura Y, Fujii N.

Chemotherapy. 2012;58(1):52-9. doi: 10.1159/000336129.

PMID:
22343392
5.

Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.

Tsui K, Wong SS, Lin LC, Tsai CR, Chen LC, Huang CH.

J Microbiol Immunol Infect. 2012 Jun;45(3):193-9. doi: 10.1016/j.jmii.2011.11.003.

6.

Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-β-lactamase-producing Escherichia coli in Japan.

Matsumura Y, Yamamoto M, Nagao M, Hotta G, Matsushima A, Ito Y, Takakura S, Ichiyama S; Kyoto-Shiga Clinical Microbiology Study Group..

J Antimicrob Chemother. 2012 Nov;67(11):2612-20. doi: 10.1093/jac/dks278.

7.

Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals.

Peirano G, Costello M, Pitout JD.

Int J Antimicrob Agents. 2010 Jul;36(1):19-23. doi: 10.1016/j.ijantimicag.2010.02.016.

PMID:
20359869
8.

High prevalence of ST131 among CTX-M-producing Escherichia coli from community-acquired infections, in the Czech Republic.

Papagiannitsis CC, Študentová V, Jakubů V, Španělová P, Urbášková P, Žemličková H, Hrabák J.

Microb Drug Resist. 2015 Feb;21(1):74-84. doi: 10.1089/mdr.2014.0070.

PMID:
25188031
9.

Molecular characterization of extended-spectrum-β-lactamase-producing and plasmid-mediated AmpC β-lactamase-producing Escherichia coli isolated from stray dogs in South Korea.

Tamang MD, Nam HM, Jang GC, Kim SR, Chae MH, Jung SC, Byun JW, Park YH, Lim SK.

Antimicrob Agents Chemother. 2012 May;56(5):2705-12. doi: 10.1128/AAC.05598-11.

10.

AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131.

Oteo J, Cercenado E, Cuevas O, Bautista V, Delgado-Iribarren A, Orden B, Pérez-Vázquez M, García-Cobos S, Campos J.

Diagn Microbiol Infect Dis. 2010 Jul;67(3):270-6. doi: 10.1016/j.diagmicrobio.2010.02.008.

PMID:
20462723
11.

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.

Oteo J, Orden B, Bautista V, Cuevas O, Arroyo M, Martínez-Ruiz R, Pérez-Vázquez M, Alcaraz M, García-Cobos S, Campos J.

J Antimicrob Chemother. 2009 Oct;64(4):712-7. doi: 10.1093/jac/dkp288.

12.

Characteristics of infections caused by extended-spectrum β-lactamase-producing Escherichia coli from community hospitals in South Africa.

Peirano G, van Greune CH, Pitout JD.

Diagn Microbiol Infect Dis. 2011 Apr;69(4):449-53. doi: 10.1016/j.diagmicrobio.2010.11.011.

PMID:
21396544
13.

National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain.

Blanco J, Mora A, Mamani R, López C, Blanco M, Dahbi G, Herrera A, Blanco JE, Alonso MP, García-Garrote F, Chaves F, Orellana MÁ, Martínez-Martínez L, Calvo J, Prats G, Larrosa MN, González-López JJ, López-Cerero L, Rodríguez-Baño J, Pascual A.

J Antimicrob Chemother. 2011 Sep;66(9):2011-21. doi: 10.1093/jac/dkr235.

14.

Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals.

Ewers C, Grobbel M, Stamm I, Kopp PA, Diehl I, Semmler T, Fruth A, Beutlich J, Guerra B, Wieler LH, Guenther S.

J Antimicrob Chemother. 2010 Apr;65(4):651-60. doi: 10.1093/jac/dkq004.

15.

Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread.

Suzuki S, Shibata N, Yamane K, Wachino J, Ito K, Arakawa Y.

J Antimicrob Chemother. 2009 Jan;63(1):72-9. doi: 10.1093/jac/dkn463.

16.

Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.

Kohner PC, Robberts FJ, Cockerill FR 3rd, Patel R.

J Clin Microbiol. 2009 Aug;47(8):2419-25. doi: 10.1128/JCM.00508-09.

17.

Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.

Simner PJ, Zhanel GG, Pitout J, Tailor F, McCracken M, Mulvey MR, Lagacé-Wiens PR, Adam HJ, Hoban DJ; Canadian Antimicrobial Resistance Alliance (CARA)..

Diagn Microbiol Infect Dis. 2011 Mar;69(3):326-34. doi: 10.1016/j.diagmicrobio.2010.10.029.

PMID:
21353961
18.

Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.

Denisuik AJ, Lagacé-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Tailor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance..

J Antimicrob Chemother. 2013 May;68 Suppl 1:i57-65. doi: 10.1093/jac/dkt027.

19.

The prevalence of plasmid-mediated AmpC beta-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China.

Ding H, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, Wang A, Deng Q, Zhang H, Wang C, Liu L, Xu X, Wang L, Shen X.

Eur J Clin Microbiol Infect Dis. 2008 Oct;27(10):915-21. doi: 10.1007/s10096-008-0532-4.

PMID:
18449580
20.

Diversity of Escherichia coli strains producing extended-spectrum beta-lactamases in Spain: second nationwide study.

Díaz MA, Hernández-Bello JR, Rodríguez-Baño J, Martínez-Martínez L, Calvo J, Blanco J, Pascual A; Spanish Group for Nosocomial Infections (GEIH)..

J Clin Microbiol. 2010 Aug;48(8):2840-5. doi: 10.1128/JCM.02147-09.

Items per page

Supplemental Content

Support Center